{"id":76517,"date":"2026-06-02T21:22:27","date_gmt":"2026-06-02T21:22:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/76517\/"},"modified":"2026-06-02T21:22:27","modified_gmt":"2026-06-02T21:22:27","slug":"ubs-lifts-valuation-on-moderna-inc-mrna-ahead-of-key-pipeline-catalysts","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/76517\/","title":{"rendered":"UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts"},"content":{"rendered":"\n

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds<\/a>. Moderna, Inc. (NASDAQ:MRNA) is among the best immunology stocks\u00a0to invest in.<\/p>\n

TheFly reported earlier this month, on May 4, that UBS increased its price objective on MRNA to $45 from $36 while continuing to hold a Neutral stance on the stock. The firm pointed to several upcoming pipeline developments that could influence investor sentiment if the company delivers favorable clinical results across its programs.<\/p>\n

More recently, on May 21, Moderna, Inc. (NASDAQ:MRNA) disclosed that its investigational mRNA influenza vaccine will undergo evaluation by an FDA advisory committee on June 18 ahead of the agency\u2019s August 5 regulatory decision deadline. The scheduled review marks a significant step in the vaccine\u2019s approval process and reflects renewed emphasis on external scientific assessment during regulatory evaluations.<\/p>\n

\"UBS UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts <\/p>\n

The advisory panel meeting is expected to examine clinical evidence supporting the vaccine candidate\u2019s safety and effectiveness before the FDA\u00a0determines\u00a0whether to authorize the product. The development also drew attention as advisory committee reviews had become less frequent in recent years for certain vaccine applications. Investors and industry observers are closely\u00a0monitoring\u00a0the outcome of the meeting, as positive feedback from the panel could strengthen confidence in Moderna\u2019s broader respiratory vaccine pipeline and support future commercial opportunities beyond its COVID-19 franchise.<\/p>\n

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in mRNA-based therapies and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, it develops treatments for infectious diseases, cancer, rare diseases, and autoimmune disorders.<\/p>\n

While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now<\/a> and 10 Most Widely Held Stocks by Individuals in 2026\u00a0<\/a>.<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. Moderna,…\n","protected":false},"author":2,"featured_media":76518,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[129],"tags":[39962,2039,39961,39960,223],"class_list":["post-76517","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ubs","tag-fda-advisory-committee","tag-inc","tag-influenza-vaccine","tag-moderna","tag-ubs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116682617423695738","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/76517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=76517"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/76517\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/76518"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=76517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=76517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=76517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}